Open-Label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients With ADPKD Receiving TolvaptanKiyotaka Uchiyama, Kaori Hayashi, Ei Kusahana et al.|Kidney International Reports|2025Cited by 16
Development of Alveolar Hemorrhage After Pfizer-BioNTech COVID-19 mRNA Vaccination in a Patient With Renal-Limited Anti-neutrophil Cytoplasmic Antibody-Associated Vasculitis: A Case ReportK Nishioka, Hiroshi Itoh, Shintaro Yamaguchi et al.|Frontiers in Medicine|2022Cited by 7
Erratum to “Open-Label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients With ADPKD Receiving Tolvaptan” [Kidney International Reports Volume 10, Issue 4, April 2025, Pages 1063-1075]Kiyotaka Uchiyama, Kaori Hayashi, Daisuke Kamano et al.|Kidney International Reports|2025Cited by 0